IKCEST

The Journal of reproductive medicine | Vol.57, Issue.9-10 | | Pages 411-4

Methotrexate on a 21-day cycle for low-risk gestational trophoblastic neoplasia.

Juan, Diaz M Bijoy, Thomas Charlotte, Paz-Pabon Enrique, Hernandez

Abstract

To perform an outcome analysis of patients with low-risk gestational trophoblastic neoplasia (GTN) treated with a 5-day intramuscular methotrexate (MTX) regimen on a 21-day cycle.A retrospective review of 31 patients with low-risk GTN treated with a 5-day MTX regimen.A total of 31 patients with low-risk GTN (WHO score < 7) received single-agent MTX at a dose of 0.4 mg/kg daily for 5 days every 21 days (mean number of cycles, 3; 83% remission). The only significant toxicity encountered was grade 2 stomatitis in 8 (26%) patients.A 5-day MTX regimen given every 21 days is convenient, well-tolerated and effective for patients with low-risk GTN.

Original Text (This is the original text for your reference.)

Methotrexate on a 21-day cycle for low-risk gestational trophoblastic neoplasia.

+More

Keywords

lowrisk gtn who score intramuscular methotrexate mtx regimen lowrisk gestational trophoblastic neoplasia

Cite this article

APA

MLA

Chicago

Juan, Diaz M Bijoy, Thomas Charlotte, Paz-Pabon Enrique, Hernandez,.Methotrexate on a 21-day cycle for low-risk gestational trophoblastic neoplasia.. 57 (9-10),411-4.

Disclaimer: The translated content is provided by third-party translation service providers, and IKCEST shall not assume any responsibility for the accuracy and legality of the content.